BioSpace News Archive

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel nonpeptide therapeutics for rare endocrine diseases and endocrine-related tumors, together with 5AM Ventures and Frazier Healthcare Partners, today announced the formation of an independently operated new company, Radionetics Oncology.

Dermata Therapeutics, Inc., a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis.

Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2021 financial results on Monday, November 1, 2021, after the market closes. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and current business trends.

Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2021, before the market opens on November 3, 2021, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Roche announced that it has entered an agreement with Ibex Medical Analytics, a global leader in artificial intelligence -based cancer diagnostics.

Orexo AB, announced the publication of a manuscript, “A Personalized, Interactive, Cognitive-Behavioral Therapy-Based Digital Therapeutic for Adjunctive Treatment of Opioid Use Disorder: Development Study,” in the Journal of Medical Internet Research Mental Health.

Ipsen and Accent Therapeutics have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture, and commercialize Accent’s pre-clinical stage METTL3 program.

Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing vaccines, announced that Valneva SE reported positive topline results from the Phase 3 pivotal trial of VLA2001, their inactivated COVID-19 vaccine candidate using Dynavax’s CpG 1018® adjuvant.

The rising government spending and the introduction of several favorable reimbursement policies are predicted to bolster global telemedicine market in the near future.

The patient infotainment terminal market is expected to observe steady growth during the forecast period of 2021-2031.